# An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

> **NCT00235794** · NA · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 50 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** temsirolimus

## Key facts

- **NCT ID:** NCT00235794
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2007-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00235794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00235794, "An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00235794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*